First-year treatment costs among new initiators of topical prostaglandin analogs: Pooled results

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 437-445

  Schmier, Jordana K ^a   Covert, David W ^b  

^a EXPONENT INC   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

Combination; Costs and cost analysis; Drug therapy; Glaucoma; Prostaglandin analogs

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BENZETHONIUM CHLORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GLAUCOMA; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; TREATMENT DURATION;

EID: 77953467037     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s10486     Document Type: Article

References (39)

1. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728-740.
2. Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144(4):533-540.
3. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863-868.
4. Stone JL, Robin AL, Novack GD, Covert DW, Cagle GD. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch Ophthalmol. 2009;127(6):732-736.
5. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116(2):191-199.
6. Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008;115(8):1320-1327.
7. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350-355.
8. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in glaucoma patients using topical intraocular pressure-lowering medications. Cornea. 2010; Apr 9. [Epub ahead of print]. doi:10.1097/ICO.0b013e3181c325b2.
9. Sit AJ, Weinreb RN, Crowston JG, Kripke DF, Liu JH. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol. 2006;141(6):1131-1133.
10. Costagliola C, Del Prete A, Verolino M, et al. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol. 2002;240(5):379-386.
11. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472-484.
12. American Academy of Ophthalmology Glaucoma Panel, Preferred Practice Patterns Committee. Primary Open-Angle Glaucoma. Limited Revision. San Francisco, CA: American Academy of Ophthalmology; 2003.
13. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446-1454.
14. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16(1):98-103.
15. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86(7): 716-726.
16. Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2: 613-621.
17. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sof Zia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27(3):339-343.
18. Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291-295.
19. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Experiment Ophthalmol. 2004;32(2):180-184.
20. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006;23(5):663-671.
21. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23(4):511-519.
22. Schmier JK, Covert DW, Robin AL. First-year treatment costs among new initators of topical prostaglandin analogs. Clin Opthalmol. 2009;3:637-644.
23. Schmier JK, Covert DW, Robin AL. First-year treatment costs among new initiators of topical prostaglandin analogs. Clin Ophthalmol. 2009;3:637-644.
24. Schmier JK, Covert DW, Robin AL. First-year treatment patterns among new initiators of topical prostaglandin analogs. Curr Med Res Opin. 2009;25(4):851-858.
25. Fremont AM, Lee PP, Mangione CM, et al. Patterns of care for open-angle glaucoma in managed care. Arch Ophthalmol. 2003;121(6): 777-783.
26. Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology. 2007;114(9):1599-1606.
27. Thomson Healthcare. Red Book Drug Topics. Montvale, NJ: Thomson Healthcare; 2009.
28. Physicians' Fee Reference: Comprehensive Fee Report: New Haven, CT: Yale Wasserman D.M.D. Medical Publishers; 2009.
29. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48(11):5052-5057.
30. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532-538.
31. Brown MM, Brown GC, Spaeth GL. Improper topical self-administration of ocular medication among patients with glaucoma. Can J Ophthalmol. 1984;19(1):2-5.
32. Ashburn FS Jr, Goldberg I, Kass MA. Compliance with ocular therapy. Surv Ophthalmol. 1980;24:237-248.
33. Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454-461.
34. Norell SE, Granstrom PA. Self-medication with pilocarpine among outpatients in a glaucoma clinic. Br J Ophthalmol. 1980;64:137-141.
35. Vanelli M, Pedan A, Liu N, Hoar J, Messier D, Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009;31(11):2628-2652.
36. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598-606.
37. Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care. 2002;8(Suppl 10):S271-S277.
38. Schwartz GF, Platt R, Reardon G, Mychaskiw MA. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology. 2007;114(4):648-652.
39. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17(3):217-222.